Primary mediastinal large B-cell lymphoma-refractory
Clinical trials for Primary mediastinal large B-cell lymphoma-refractory explained in plain language.
Never miss a new study
Get alerted when new Primary mediastinal large B-cell lymphoma-refractory trials appear
Sign up with your email to follow new studies for Primary mediastinal large B-cell lymphoma-refractory, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 'Double Punch' CAR T-Cell therapy takes on tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called GF-CART01 for people with certain B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two cancer markers (CD…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY
Phase 1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo aims to boost CAR T-Cell therapy for rare lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard CAR T-cell therapy can improve outcomes for people with relapsed or refractory primary mediastinal B-cell lymphoma. About 35 participants will receive pembrolizumab before and afte…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY
Phase 2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail aims to boost CAR T-Cell success in lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding two drugs—CC-99282 and rituximab—can help people with non-Hodgkin lymphoma who didn't get a good result from CAR T-cell therapy. The study will enroll 18 adults with relapsed or refractory B-cell lymphoma. Researchers are looking f…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA-REFRACTORY
Phase 1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC